Imjudo (Tremelimumab) in Combination with Imfinzi Approved in the US for Patients with Unresectable Liver Cancer

0
128
AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable HCC.
[AstraZeneca Inc.]
Press Release